Valium (diazepam) is a benzodiazepine derivative, called an anxiolytic, that belongs in a group of central nervous system depressants. It enhances the activity of the major inhibitory neurotransmitter in the central nervous system, slowing it down. Diazepam is used in the treatment of many medical conditions. In multiple sclerosis (MS), its primary purpose is to relieve muscle spasms and spasticity.

Some side effects of diazepam are drowsiness, feeling tired, muscle weakness, or loss of coordination.

Valium is available in generic form.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

More Trials Needed to Clarify Benefits of Alzheimer’s Therapy Memantine in MS

Treatment of up to a year with memantine — an approved therapy for Alzheimer’s disease — failed to prevent cognitive decline and disability, and to significantly reduce fatigue and spasticity in adults with multiple sclerosis (MS), a review of published studies shows. The therapy, sold under the brand name Namenda, works by preventing glutamate — a nerve-signaling molecule previously […]

GW Pharma Plans More Clinical Trials for Sativex

GW Pharmaceuticals is planning to continue recruiting patients into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as a potential add-on therapy for people with multiple sclerosis (MS) and spasticity. The company also is planning to launch three additional clinical trials in the U.S. […]

Phase 3 Trial of Sativex, Cannabis Extract Treatment for MS Spasticity, Opens in US

A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS). Sativex, by GW Pharmaceuticals, is available in 25 countries — including most of Europe and Canada — as […]

FDA Will Review Arbaclofen ER, Potential Oral Therapy for MS Spasticity

The U.S. Food and Drug Administration (FDA) has agreed to review  Osmotica Pharmaceuticals‘ amended request for the approval of arbaclofen extended release (ER) tablets to treat spasticity in people with multiple sclerosis (MS), the company announced. The regulatory agency found that the new drug application addressed all issues raised in a July 2016 action letter response to the […]

Trial of Cannabis Derivatives in Treating MS Spasticity to Open in Canada

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other symptoms of multiple sclerosis (MS). The money, worth about […]

Osmotica Amends NDA for Arbaclofen ER to Treat MS Spasticity

Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticity in people with multiple sclerosis (MS). Arbaclofen ER (brand name Ontinua), is an extended release formulation of arbaclofen, a compound similar to the muscle […]

Spasticity Scales May Not Reflect Sativex Benefits in MS Patients, Study Suggests

Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy. The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to reflect the therapy’s overall benefits beyond spasticity itself. […]

Nimodipine Can Prevent Spasticity Following Spinal Cord Injury, Mouse Study Shows

Nimodipine, an approved medication to prevent brain damage caused by hemorrhage, can be used to prevent spasticity following a spinal cord injury, a mouse study shows. In addition to spinal cord injury, nimodipine may be a promising treatment for neurodegenerative disorders such as multiple sclerosis (MS) and amyotrophic lateral sclerosis, in which spasticity often develops, investigators noted. […]

MS Patients Find Cannabis Helpful for Easing Pain, Spasticity, Study Reports

About 85% of people with multiple sclerosis (MS) using cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis,” was published in the journal Multiple Sclerosis and Related Disorders. A previous review study that examined the […]